Questions about the integrity of a single clinical trial have cost a rare-disease medicine its place on the European market. The European Medicines Agency’s human medicines committee, the CHMP, has recommended revoking the marketing authorisation for Tavneos, known generically as avacopan, after concluding that its benefits can no longer be shown to outweigh its risks. The drug is used to treat adults with two uncommon and serious inflammatory conditions of the blood vessels, granulomatosis with polyangiitis and microscopic polyangiitis.
The reversal is unusual because it turns not on a new safety signal in patients but on the evidence base itself. The committee opened its review to examine information raising questions about the data integrity of the Advocate study, the pivotal trial that underpinned approval. Once regulators lose confidence that a trial’s results reliably reflect how a medicine performs, the benefit side of the risk-benefit ledger effectively collapses, whatever the drug’s theoretical mechanism. That is what appears to have happened here.
The European action does not stand alone. The New England Journal of Medicine retracted the paper reporting the Advocate results, and regulators on both sides of the Atlantic have moved in the same direction, with the United States Food and Drug Administration also acting against the product. For the manufacturers, the episode is a costly setback and a reminder that post-approval scrutiny can unwind a launch years after the fact.
For the small number of European patients taking Tavneos, the recommendation raises immediate practical questions about alternatives and managed withdrawal. Both conditions the drug treats are severe, and established therapies exist, but any switch in a rare, life-threatening illness demands careful clinical handling. National authorities and treating specialists will need clear guidance to avoid leaving patients without effective options during the transition.
The Tavneos decision landed alongside a busier and more routine set of recommendations from the same June meeting, underlining that the committee’s core work remains expanding the medicine cabinet rather than shrinking it. The CHMP backed six new medicines for approval, including Aujemflu, an influenza vaccine aimed at people aged 50 and over; Hopledo, a levodopa and carbidopa combination for Parkinson’s patients with moderate-to-severe motor fluctuations; and Onswik, an insulin for adults with type 2 diabetes. A further twelve medicines were recommended for wider use through extensions of their existing indications.
The contrast is instructive. A regulator willing to strip authorisation from an approved product on evidentiary grounds signals that the gate does not lock shut once a drug is on the market, a stance that matters as the EU finalises its long-running overhaul of pharmaceutical legislation. That reform has centred on speeding access to innovative treatments while tightening the system’s ability to monitor them afterwards, and cases like this one test whether the post-market half of that bargain has teeth.
Defenders of the industry will note that a single flawed trial should not indict a wider pipeline, and that avacopan’s removal reflects a specific data problem rather than a systemic failure. Patient advocates, by contrast, are likely to ask how a study with integrity concerns cleared the original bar. The answer will shape how much confidence the public places in the accelerated approvals the new legislation is designed to deliver. For now, the message from Amsterdam is that authorisation is a continuing test, not a one-time verdict.
